EUVIMEDEUVIMED entdecken
Crossref

The use of belimumab in three cases of refractory lupus nephritis

Aruni Malaweera iD, Sukhpal Dayan, Rebecca Pellicano, Alberta Hoi, A Richard Kitching, Joanna R Kent

Internal Medicine Journal · 2023

DOI: 10.1111/imj.16242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Aruni Malaweera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Monash Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent trials for the treatment of systemic lupus erythematosus (SLE), belimumab (BLM), in addition to standard immunosuppression, has been shown to improve renal and nonrenal outcomes. We report our experience using BLM in three cases of refractory lupus nephritis (LN), where renal remission was not achieved using cyclophosphamide, mycophenolate mofetil and other immunosuppressive medications. In two of the three cases, BLM therapy led to a partial remission of LN, improvement in serological markers of SLE and disease activity, which permitted a reduction in prednisolone dosing. Treatment with efficacious therapies early in the course of LN is a desirable therapeutic strategy, to achieve early remission of proteinuria and curtail the development of irreversible chronic renal damage. Further studies are needed to provide information on the effectiveness of BLM for maintenance of remission, prevention of flares and monitoring for long‐term complications of B‐cell modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisLupus Erythematosus, SystemicHumansImmunosuppressive AgentsAntibodies, Monoclonal, HumanizedTreatment Outcome

Stichwörter der Autor:innen

belimumablupusrefractory

Substanzen

belimumabImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Nephrology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Pathology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Medicine, Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Aruni Malaweera

Zitieren

APA

Malaweera, A., Dayan, S., Pellicano, R., Hoi, A., Kitching, A. R., & Kent, J. R. (2023). The use of belimumab in three cases of refractory lupus nephritis. Internal Medicine Journal. https://doi.org/10.1111/imj.16242

Vancouver

Malaweera A, Dayan S, Pellicano R, Hoi A, Kitching AR, Kent JR. The use of belimumab in three cases of refractory lupus nephritis. Internal Medicine Journal. 2023. doi:10.1111/imj.16242

BibTeX
@article{Malaweera2023,
  author = {Malaweera, Aruni and Dayan, Sukhpal and Pellicano, Rebecca and Hoi, Alberta and Kitching, A Richard and Kent, Joanna R},
  title = {The use of belimumab in three cases of refractory lupus nephritis},
  journal = {Internal Medicine Journal},
  year = {2023},
  doi = {10.1111/imj.16242}
}
Kostenlos starten →